this is unexpected, but very welcome
The incidence of heart attacks and strokes were reduced by 60% over a median follow-up period of 30
months following a single dose of rexlemestrocel-L in the population of 537 patients with New York
Heart Association (NYHA) class II or III chronic heart failure (5% vs 13%, p=0.002). Patients who
received rexlemestrocel-L had a 68% reduction in the rate of recurrent hospitalizations from non-fatal
heart attacks or strokes compared with controls, with a hospitalization rate of 1.90 per 100 patientyears of follow-up in the rexlemestrocel-L arm versus 5.95 per 100 patient-years of follow-up in the
control arm (p=0.0002).
V
-
- There are more pages in this discussion • 224 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.025(1.55%) |
Mkt cap ! $2.031B | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $6.345M | 3.987M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 44493 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 4159 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |